Annual Reports Agreement

In accordance with the Terms of Use of these websites it is forbidden to use the photographs contained in the Annual Reports posted on the websites for any purposes other than for exclusively personal and non-commercial use and to duplicate, alter, modify, rearrange or otherwise tamper with the photographs contained in the Annual Reports and disseminate any such altered, modified, rearranged or otherwise affected photographs. You may retrieve and display the content of the Annual Reports including photographs on a computer or mobile telephone screen, print individual pages on paper (but not photocopy them) and store such pages in electronic form on disk or on your mobile telephone (but not on any server or other storage device connected to for your personal, non-commercial use only.)

Do you agree with the above stated terms of use of the Annual Reports?

Yes No

Downloading

Other Companies

Cytune Pharma SAS

PPF Group owns a French biotechnology company Cytune Pharma SAS focused on researching and developing new therapies for immune modulation aimed at enhancing immune response of patients suffering from cancer and infectious diseases.
www.cytunepharma.com

Accord Research

Accord Research is an independent Clinical Research Organization (CRO) fully incorporated into the PPF Group. The company is primarily dedicated to provide clinical research services for PPF’s biotechnology company SOTIO but also to third parties. The company is operating in Europe and USA with its own employees or on the basis of a long term subcontracted cooperation.
www.accord-research.com

Autolus Therapeutics

Autolus Therapeutics plc (“Autolus”) is a leader in bio T cell programming technologies and is developing a pipeline of next generation T cell therapies targeting both hematological cancers and solid tumors. Focused on the development of precisely targeted, controlled and highly active CAR-T cell products, Autolus aims to provide T cell therapies with very favorable safety profile and enhanced clinical efficacy to better recognize cancer cells, break down their defense mechanisms, and attack and kill these cells.
www.autolus.com

Back to portfolio